Abstract: The present disclosure in various aspects provides methods for making pharmaceutical compositions for treating neurodegenerative diseases (e.g., demyelinating diseases), such as but not limited to multiple sclerosis, neuromyelitis optica, and transverse myelitis. The pharmaceutical compositions impact specific antibody-mediated processes involved in the biology of neurodegenerative disease. In certain aspects, the disclosure provides pharmaceutical compositions for treating neurodegenerative disease, which are based on inhibiting the action of pathologic antibodies, or alternatively providing antibodies to stimulate neuroprotection or repair processes.
Type:
Application
Filed:
May 12, 2017
Publication date:
September 8, 2022
Applicant:
The Board of Regents of the University of Texas System
Abstract: Identification and evaluation of a set of first-in-class potent inhibitors targeting a new cancer target, Grb2-associated binder-1 (GAB1), which integrates signals from different signaling pathways and is frequently over-expressed in cancer cells. Intensive computational modeling is utilized to understand the structure of the GAB1 pleckstrin homology (PH) domain and screened five million compounds. Upon biological evaluation, several inhibitors were found that induced large conformational changes of the target structure exhibited strong selective binding to GAB1 PH domain. Particularly, these inhibitors demonstrated potent and tumor-specific cytotoxicity in breast cancer cells. This targeting GAB1 signaling may be used for cancer therapy, especially for triple negative breast cancer patients.
Type:
Grant
Filed:
October 10, 2019
Date of Patent:
September 6, 2022
Assignees:
Arizona Board of Regents on Behalf of the University of Arizona, Board of Regents, The University of Texas System
Inventors:
Emmanuelle J. Meuillet, Shuxing Zhang, Lu Chen
Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
Type:
Grant
Filed:
September 1, 2020
Date of Patent:
September 6, 2022
Assignees:
Board of Regents, The University of Texas System, ChemPartner Corporation
Inventors:
Maria Emilia Di Francesco, Philip Jones, Christopher Lawrence Carroll, Jason Bryant Cross, Suyambu Kesava Vijayan Ramaswamy, Michael Garrett Johnson, Sarah Lively, David Lapointe
Abstract: The disclosure provides methods and compositions for treating and diagnosing tauopathies. More specifically, the disclosure relates to the identification of epitopes on tau and their use as vaccines or as reagents to generate monoclonal antibodies that can be used for both diagnosis and treatment of tau-related diseases.
Type:
Application
Filed:
November 18, 2019
Publication date:
September 1, 2022
Applicant:
The Board of Regents of the University of Texas System
Inventors:
Marc I. DIAMOND, Kenneth DROMBOSKY, Dailu CHEN, Victor MANON, Xiaohua LIU, Hamid MIRZAEI, Jaime VAQUER-ALICEA, Hilda MIRBAHA, Lukasz A. JOACHIMIAK
Abstract: A vat resin for three-dimensional stereolithography printing of a thiourethane polymer part comprising a liquid mixture including a first type of monomer, a second type of monomer, a photolatent base decomposable upon exposure to a light to form a non-nucleophillic base catalyst having a pKa greater than 7, an anionic step-growth polymerization reaction inhibitor having an acidic group configured to form an acid-base pair with the non-nucleophillic base and a light absorber having an absorbance in the liquid mixture that is greater than an absorbance of the photolatent base at a wavelength of the light used for the exposure. Methods of preparing the vat resin and three-dimensional stereolithography printing a thiourethane polymer part using the vat resin are also disclosed.
Type:
Grant
Filed:
October 25, 2018
Date of Patent:
August 30, 2022
Assignees:
Board of Regents, The University of Texas System, Adaptive 3D Technologies
Inventors:
Gregory T. Ellson, Benjamin R. Lund, Walter Voit
Abstract: Described herein are portable apparatuses and methods of creating fibers, such as microfibers and nanofibers. The methods discussed herein employ centrifugal forces to transform material into fibers. Portable apparatuses that may be used to create fibers are described.
Type:
Grant
Filed:
February 19, 2020
Date of Patent:
August 30, 2022
Assignee:
The Board of Regents of the University of Texas System
Inventors:
Karen Lozano, Gregory Potter, Javier Alonzo Ortega
Abstract: Disclosed herein are dendritically porous three-dimensional structures, including hierarchical dendritically porous three-dimensional structures. The structures include metal foams and graphite structures, and are useful in energy storage devices as well as chemical catalysis.
Type:
Grant
Filed:
March 8, 2018
Date of Patent:
August 30, 2022
Assignee:
Board of Regents, The University of Texas System
Abstract: This disclosure provides multimeric binding molecules that bind to SARS-CoV-2. This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating and preventing coronavirus disease 2019 (COVID-19).
Type:
Application
Filed:
February 15, 2022
Publication date:
August 25, 2022
Applicants:
The Board of Regents of The University of Texas System, IGM Biosciences, Inc.
Inventors:
Zhiqiang KU, Xuping XIE, Paul HINTON, Ningyan ZHANG, Bruce KEYT, Dean NG, Stephen CARROLL, Pei-Yong SHI, Zhiqiang AN
Abstract: A method of treating or preventing a sickle cell disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting immature hematopoietic cells into the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of non-GVHD inducing anti-third party cells comprising cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and capable of homing to the lymph nodes following transplantation.
Type:
Application
Filed:
May 5, 2022
Publication date:
August 25, 2022
Applicants:
Yeda Research and Development Co. Ltd., Board of Regents, The University of Texas System
Abstract: Embodiments of the present disclosure pertain to methods of monitoring an environment for the presence of a solvent by: (i) exposing the environment to a luminescent compound, where the relative luminescence emission intensity of the luminescent compound changes upon interaction with the solvent; and (ii) monitoring a change in the relative luminescence emission intensity of the luminescent compound, where the absence of the change indicates the absence of the solvent from the environment, and where the presence of the change indicates the presence of the solvent in the environment. The luminescent compounds include a phosphorous atom with one or more carboxyl groups, where the carboxyl groups are coordinated with one or more metallic ions (e.g., lanthanide ions and yttrium ions). The present disclosure also pertains to sensors for monitoring an environment for the presence of a solvent, where the sensors include one or more of the aforementioned luminescent compounds.
Type:
Application
Filed:
May 9, 2022
Publication date:
August 25, 2022
Applicant:
Board of Regents, The University of Texas System
Inventors:
Simon M. Humphrey, Bradley J. Holliday, Matthew D. Moore, Samuel G. Dunning
Abstract: Aspects of the disclosure relate to a method for treating EGFR-mutant non-small-cell lung cancer (NSCLC) in a patient comprising administering a CD70 targeting molecule to the patient. Further aspects of the disclosure relate to a method for treating an epithelial-to-mesenchymal transition (EMT)-positive NSCLC in a patient comprising administering a CD70-targeting molecule to the patient.
Type:
Application
Filed:
May 14, 2020
Publication date:
August 25, 2022
Applicant:
Board of Regents, The University of Texas System
Abstract: The present disclosure pertains to methods and systems for separating olefins from a mixture that includes olefins and non-olefins. The methods include associating the mixture with a support that is embedded with an ionic liquid and a metal ion. The ionic liquid prevents the substantial reduction of the metal ion by reducing agents while the metal ion mediates the transport of the olefin through the support by selectively and reversibly coupling with the olefin. In some embodiments, the support may be in the form of supported ionic liquid porous membranes, and the ionic liquid may be held within the pores of the support by capillary forces. In some embodiments, the support may be in the form of a composite, and the ionic liquid may be dispersed throughout the composite. In some embodiments, the metal ion may be dissolved in the ionic liquid and dispersed throughout the support.
Type:
Grant
Filed:
June 10, 2019
Date of Patent:
August 23, 2022
Assignee:
Board of Regents, The University of Texas System
Inventors:
Joan F. Brennecke, Benny D. Freeman, Constanza Miguel Sanchez
Abstract: A method of synthesizing a smart paper transformer is provided. The method comprises combining paper with HAuCl4 and stirring together in an aqueous solution to form a pulp. The pulp is treated with NaBH4 aqueous solution. The treated pulp is then washed and centrifuged with water a number of times to form a gold nanosponge (AuNS) catalyst pulp.
Type:
Grant
Filed:
November 18, 2019
Date of Patent:
August 23, 2022
Assignee:
Board of Regents, The University of Texas System
Abstract: Provided herein are polypeptides comprising membrane-anchored IL-12. Also provided herein are T cells expressing the membrane-anchored IL-12. Further, methods of treating cancer comprising administering T cells expressing membrane-anchored IL-12 are provided herein. Also provided are combination treatments comprising T cells expressing membrane-anchored IL-12 and T cell chemoattractant-inducing chemokines. In addition, methods are provided for activating T cells to express NKG2D and methods of their use in the treatment of cancer.
Type:
Grant
Filed:
October 6, 2017
Date of Patent:
August 23, 2022
Assignee:
Board of Regents, The University of Texas System
Abstract: A method, system and computer program product for segmenting generic foreground objects in images and videos. For segmenting generic foreground objects in videos, an appearance stream of an image in a video frame is processed using a first deep neural network. Furthermore, a motion stream of an optical flow image in the video frame is processed using a second deep neural network. The appearance and motion streams are then joined to combine complementary appearance and motion information to perform segmentation of generic objects in the video frame. Generic foreground objects are segmented in images by training a convolutional deep neural network to estimate a likelihood that a pixel in an image belongs to a foreground object. After receiving the image, the likelihood that the pixel in the image is part of the foreground object as opposed to background is then determined using the trained convolutional deep neural network.
Type:
Grant
Filed:
December 5, 2017
Date of Patent:
August 23, 2022
Assignee:
Board of Regents, The University of Texas System
Inventors:
Kristen Grauman, Suyog Dutt Jain, Bo Xiong
Abstract: Sheath-run artificial muscles (or SRAMs) are described in which the dimensional changes and/or modulus changes of a sheath on the surface of a twisted or coiled host yarn or fiber drives torsional and tensile actuation. The sheath-core artificial muscle includes a sheath on a coiled core yarn or fiber that has inserted twist, in which the sheath does not include a yarn, the coiled core yarn or fiber includes a core yarn or fiber, the sheath can change volume, modulus, or a combination thereof when actuated by an influence source to drive actuation, and the influence source is selected from a group consisting of absorption processes, desorption processes, changes in temperature, changes in external pressure, changes in a magnetic field, changes in an electric field, exposures to actinic radiation, electrochemical charge and discharge, chemical reactions, and combinations thereof.
Type:
Application
Filed:
May 7, 2020
Publication date:
August 18, 2022
Applicant:
Board of Regents, The University of Texas System
Inventors:
Ray H. Baughman, Jiuke Mu, Monica Jung De Andrade, Shaoli Fang, Na Li, Carter S. Haines
Abstract: Disclosed herein are compounds and methods for the inhibition of the RNF1 or RNF2 subunit of polycomb repressive complex 1 (PRC1) for the treatment of metastatic cancer, such as metastatic castration-resistant prostate cancer. The inhibitors can be combined with checkpoint inhibitors such as PD-1 inhibitors, PD-L 1 inhibitors, or CTLA-4 inhibitors.
Type:
Application
Filed:
June 26, 2020
Publication date:
August 18, 2022
Applicants:
Board of Regents, The University of Texas System, Memorial Sloan Kettering Cancer Center
Inventors:
Filippo Giancotti, Ouathek Ouerfelli, Wenjing Su, Guangli Yang, Howard Scher, Mohammad Marzabadi
Abstract: Disclosed herein are methods for modulating an amount or activity of a gene or a gene product in a cell. The methods herein may comprise contacting a cell with a therapeutic agent assembled with a lipid composition, which lipid composition may comprise a dendrimer or dendron which may comprise one or more degradable diacyl group, in which may result in modulating the amount or activity of the gene or the gene product in the cell. The therapeutic agent modulating a gene or gene product in a cell may be sufficient to treat a disease or disorder in a subject. Further disclosed herein are pharmaceutical compositions, kits, and lipid compositions for modulating an amount or activity of a gene or a gene product in a cell.
Type:
Application
Filed:
December 30, 2021
Publication date:
August 18, 2022
Applicant:
The Board of Regents of The University of Texas System
Abstract: In one aspect, described is a magnetic-core inductor design approach that leverages NiZn ferrites with low loss at RF, distributed gaps and field balancing to achieve improved performance eat tens of MHz and at hundreds of watts and above. Also described is an inductor design which achieves “self-shielding” in which the magnetic field generated by the element is wholly contained within the physical volume of the structure rather than extending into space as a conventional air-core inductor would. This approach enables significant reductions of system enclosure volume and improvements in overall system efficiency.
Type:
Application
Filed:
February 18, 2022
Publication date:
August 18, 2022
Applicants:
Massachusetts Institute of Technology, The Trustees of Dartmouth College, Board of Regents, The University of Texas System
Inventors:
Roderick S. BAYLISS, III, David J. PERREAULT, Charles SULLIVAN, Rachel S. YANG, Alex J. HANSON
Abstract: Provided herein are methods of treating patients with a combination of an anti-folate agent and an A2BR antagonist. Also provided are methods of treating patients with a combination of an anti-folate agent and an immune checkpoint inhibitor. The patients are selected for treatment based on having an MTAP-deficient cancer.
Type:
Application
Filed:
June 15, 2020
Publication date:
August 18, 2022
Applicant:
Board of Regents, The University of Texas System